latest update:
[TrialBase DB]

trial summary · NCT07725523

Safety and Efficacy of OTL78

Safety and Efficacy of OTL78, a PSMA-targeted Fluorescent Agent, for Intraoperative Imaging of Prostate Cancer: A Phase IIb Trial Randomized Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition Prostate Cancer Surgery, sponsored by Clinton Bahler. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07725523phase PHASE2/PHASE3enrollment 45start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a trial to assess the accuracy of an imaging agent, PSMA targeted fluorescent dye OTL78 (zopocianine), in combination with Near InfraRed (NIR) fluorescent imaging, to improve the detection of malignant (growing in an uncontrolled way) tissue in adult patients undergoing standard of care prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. This trial is intended to confirm results from previous Phase 2 dose finding studies and to support the dose selection for subsequent Phase 3 development.

Source record: https://clinicaltrials.gov/study/NCT07725523

Facts

registry idNCT07725523
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2/PHASE3
study typeINTERVENTIONAL
lead conditionProstate Cancer Surgery
sponsorClinton Bahler
sponsor classOTHER
enrollment45
start date2026-12
primary completion2027-07
completion2027-09
results postednot reported

Conditions

  • Prostate Cancer Surgery
  • Prostate Cancer Metastatic Disease

Interventions

  • 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery

Countries

  • United States

Intervention types: DRUG

Work with this record